Drug search by name

Bosentan Tablets for Oral Suspension and Hepatotoxicity/liver impairment

Result of checking the interaction of drug Bosentan Tablets for Oral Suspension and disease Hepatotoxicity/liver impairment for safety when used together.

Check result:

Bosentan Tablets for Oral Suspension <> Hepatotoxicity/liver impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure. Hepatic function should be assessed before treatment initiation and closely monitored during treatment. Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice. Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult. In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.

Bosentan Tablets for Oral Suspension

Generic Name: bosentan

Brand Name: Tracleer

Synonyms: Bosentan

What is Bosentan Tablets for Oral Suspension?